Diabetic cardiovascular autonomic neuropathy: clinical implications

References

• Tesfaye S, Boulton AJ, Dyck PJ et al.; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33(10), 2285–2293 (2010).
   PubMed Web of Science ®Google Scholar
• Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 26(5), 1553–1579 (2003).
   PubMed Web of Science ®Google Scholar
• Vinik AI, Erbas T. Recognizing and treating diabetic autonomic neuropathy. Cleve. Clin. J. Med. 68(11), 928–930, 932, 934 (2001).
   PubMedGoogle Scholar
• Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 115(3), 387–397 (2007).
   PubMed Web of Science ®Google Scholar
• Nehlig A, Coles JA. Cellular pathways of energy metabolism in the brain: is glucose used by neurons or astrocytes? Glia 55(12), 1238–1250 (2007).
   PubMedGoogle Scholar
• Verrotti A, Loiacono G, Mohn A, Chiarelli F. New insights in diabetic autonomic neuropathy in children and adolescents. Eur. J. Endocrinol. 161(6), 811–818 (2009).
   PubMedGoogle Scholar
• Nishimura C, Lou MF, Kinoshita JH. Depletion of myo-inositol and amino acids in galactosemic neuropathy. J. Neurochem. 49(1), 290–295 (1987).
   PubMedGoogle Scholar
• Greene DA, Lattimer SA. Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozocin diabetes and its correction by dietary myo-inositol supplementation. J. Clin. Invest. 72(3), 1058–1063 (1983).
   PubMed Web of Science ®Google Scholar
• Greene DA, Lattimer SA, Sima AA. Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy? Diabetes 37(6), 688–693 (1988).
   PubMed Web of Science ®Google Scholar
• Veves A, King GL. Can VEGF reverse diabetic neuropathy in human subjects? J. Clin. Invest. 107(10), 1215–1218 (2001).
   PubMed Web of Science ®Google Scholar
• Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J. 16(1), 123–125 (2002).
   PubMed Web of Science ®Google Scholar
• Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 46(Suppl. 2), S31–S37 (1997).
   PubMed Web of Science ®Google Scholar
• Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 46(Suppl. 2), S38–S42 (1997).
   PubMed Web of Science ®Google Scholar
• Hoeldtke RD, Bryner KD, McNeill DR et al. Nitrosative stress, uric acid, and peripheral nerve function in early Type 1 diabetes. Diabetes 51(9), 2817–2825 (2002).
   PubMedGoogle Scholar
• Vinik AI, Erbas T, Park TS, Stansberry KB, Scanelli JA, Pittenger GL. Dermal neurovascular dysfunction in Type 2 diabetes. Diabetes Care 24(8), 1468–1475 (2001).
   PubMedGoogle Scholar
• Lukic IK, Humpert PM, Nawroth PP, Bierhaus A. The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy. Ann. NY Acad. Sci. 1126, 76–80 (2008).
   PubMed Web of Science ®Google Scholar
• Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44(11), 1973–1988 (2001).
   PubMed Web of Science ®Google Scholar
• Toth C, Rong LL, Yang C et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 57(4), 1002–1017 (2008).
   PubMed Web of Science ®Google Scholar
• Purves T, Middlemas A, Agthong S et al. A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J. 15(13), 2508–2514 (2001).
   PubMed Web of Science ®Google Scholar
• Purves TD, Tomlinson DR. Are mitogen-activated protein kinases glucose transducers for diabetic neuropathies? Int. Rev. Neurobiol. 50, 83–114 (2002).
   PubMedGoogle Scholar
• Wittmack EK, Rush AM, Hudmon A, Waxman SG, Dib-Hajj SD. Voltage-gated sodium channel Nav1.6 is modulated by p38 mitogen-activated protein kinase. J. Neurosci. 25(28), 6621–6630 (2005).
   PubMed Web of Science ®Google Scholar
• Cheng C, Zochodne DW. Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 52(9), 2363–2371 (2003).
   PubMed Web of Science ®Google Scholar
• Obrosova IG. How does glucose generate oxidative stress in peripheral nerve? Int. Rev. Neurobiol. 50, 3–35 (2002).
   PubMedGoogle Scholar
• Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabó E, Szabó C. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51(2), 514–521 (2002).
   PubMed Web of Science ®Google Scholar
• Obrosova IG, Li F, Abatan OI et al. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53(3), 711–720 (2004).
   PubMed Web of Science ®Google Scholar
• Pittenger GL, Malik RA, Burcus N, Boulton AJ, Vinik AI. Specific fiber deficits in sensorimotor diabetic polyneuropathy correspond to cytotoxicity against neuroblastoma cells of sera from patients with diabetes. Diabetes Care 22(11), 1839–1844 (1999).
   PubMedGoogle Scholar
• Sundkvist G, Lind P, Bergström B, Lilja B, Rabinowe SL. Autonomic nerve antibodies and autonomic nerve function in Type 1 and Type 2 diabetic patients. J. Intern. Med. 229(6), 505–510 (1991).
   PubMedGoogle Scholar
• Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 634(1), 7–12 (1994).
   PubMed Web of Science ®Google Scholar
• Horrobin DF. Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes 46(Suppl. 2), S90–S93 (1997).
   PubMedGoogle Scholar
• Vinik AI, Anandacoomaraswamy D, Ullal J. Antibodies to neuronal structures: innocent bystanders or neurotoxins? Diabetes Care 28(8), 2067–2072 (2005).
   PubMedGoogle Scholar
• Brussee V, Cunningham FA, Zochodne DW. Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 53(7), 1824–1830 (2004).
   PubMed Web of Science ®Google Scholar
• Toth C, Brussee V, Zochodne DW. Remote neurotrophic support of epidermal nerve fibres in experimental diabetes. Diabetologia 49(5), 1081–1088 (2006).
   PubMed Web of Science ®Google Scholar
• Singhal A, Cheng C, Sun H, Zochodne DW. Near nerve local insulin prevents conduction slowing in experimental diabetes. Brain Res. 763(2), 209–214 (1997).
   PubMed Web of Science ®Google Scholar
• Spallone V, Ziegler D, Freeman R et al. on behalf of the Toronto Consensus Panel on Diabetic Neuropathy*. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab. Res. Rev. 27(7), 639–653 (2011).
   PubMed Web of Science ®Google Scholar
• The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 41, 416–423 (1998).
   PubMed Web of Science ®Google Scholar
• Kennedy WR, Navarro X, Sutherland DE. Neuropathy profile of diabetic patients in a pancreas transplantation program. Neurology 45(4), 773–780 (1995).
   PubMed Web of Science ®Google Scholar
• Kennedy WR, Navarro X, Goetz FC, Sutherland DE, Najarian JS. Effects of pancreatic transplantation on diabetic neuropathy. N. Engl. J. Med. 322(15), 1031–1037 (1990).
   PubMed Web of Science ®Google Scholar
• Ziegler D, Gries FA, Spüler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J. Diabetes Complicat. 6(1), 49–57 (1992).
   PubMedGoogle Scholar
• Neil HA, Thompson AV, John S, McCarthy ST, Mann JI. Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population. Diabet. Med. 6(1), 20–24 (1989).
   PubMedGoogle Scholar
• O’Brien IA, O’Hare JP, Lewin IG, Corrall RJ. The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. Q. J. Med. 61(234), 957–967 (1986).
   PubMedGoogle Scholar
• Ziegler D, Gries FA, Mühlen H, Rathmann W, Spüler M, Lessmann F. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. The Diacan Multicenter Study Group. Diabete Metab. 19(1 Pt 2), 143–151 (1993).
   PubMed Web of Science ®Google Scholar
• Valensi P, Pariès J, Attali JR; French Group for Research and Study of Diabetic Neuropathy. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications – the French multicenter study. Metab. Clin. Exp. 52(7), 815–820 (2003).
   PubMed Web of Science ®Google Scholar
• Low PA, Benrud-Larson LM, Sletten DM et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 27(12), 2942–2947 (2004).
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Low PA, Waberski BH et al.; DCCT/EDIC Research Group. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in Type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 119(22), 2886–2893 (2009).
   PubMed Web of Science ®Google Scholar
• Putz Z, Tabák AG, Tóth N et al. Noninvasive evaluation of neural impairment in subjects with impaired glucose tolerance. Diabetes Care 32(1), 181–183 (2009).
   PubMed Web of Science ®Google Scholar
• Stevens MJ, Raffel DM, Allman KC et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 98(10), 961–968 (1998).
   PubMed Web of Science ®Google Scholar
• Sampson MJ, Wilson S, Karagiannis P, Edmonds M, Watkins PJ. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. Q. J. Med. 75(278), 635–646 (1990).
   PubMedGoogle Scholar
• Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q. J. Med. 49(193), 95–108 (1980).
   PubMedGoogle Scholar
• Ko SH, Park SA, Cho JH et al. Progression of cardiovascular autonomic dysfunction in patients with Type 2 diabetes: a 7-year follow-up study. Diabetes Care 31(9), 1832–1836 (2008).
   PubMedGoogle Scholar
• Tesfaye S, Chaturvedi N, Eaton SE et al.; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 352(4), 341–350 (2005).
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with Type 2 diabetes mellitus and microalbuminuria: the Steno Type 2 randomised study. Lancet 353(9153), 617–622 (1999).
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med. 348(5), 383–393 (2003).
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Francis DP, Rubens MB, Underwood SR, Fuller JH. The association of heart-rate variability with cardiovascular risk factors and coronary artery calcification: a study in Type 1 diabetic patients and the general population. Diabetes Care 24(6), 1108–1114 (2001).
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Olson JC, Erbey JR et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in Type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 26(5), 1374–1379 (2003).
   PubMed Web of Science ®Google Scholar
• Rolim LC, Sá JR, Chacra AR, Dib SA. Diabetic cardiovascular autonomic neuropathy: risk factors, clinical impact and early diagnosis. Arq. Bras. Cardiol. 90(4), e24–e31 (2008).
   Google Scholar
• Ziegler D, Zentai C, Perz S et al.; KORA Study Group. Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population. Exp. Clin. Endocrinol. Diabetes 114(4), 153–159 (2006).
   PubMed Web of Science ®Google Scholar
• Moran A, Palmas W, Field L et al. Cardiovascular autonomic neuropathy is associated with microalbuminuria in older patients with Type 2 diabetes. Diabetes Care 27(4), 972–977 (2004).
   PubMed Web of Science ®Google Scholar
• Witte DR, Tesfaye S, Chaturvedi N, Eaton SE, Kempler P, Fuller JH; EURODIAB Prospective Complications Study Group. Risk factors for cardiac autonomic neuropathy in Type 1 diabetes mellitus. Diabetologia 48(1), 164–171 (2005).
   PubMed Web of Science ®Google Scholar
• Burger AJ, Weinrauch LA, D’Elia JA, Aronson D. Effect of glycemic control on heart rate variability in Type I diabetic patients with cardiac autonomic neuropathy. Am. J. Cardiol. 84(6), 687–691 (1999).
   PubMedGoogle Scholar
• Mäkimattila S, Schlenzka A, Mäntysaari M et al. Predictors of abnormal cardiovascular autonomic function measured by frequence domain analysis of heart rate variability and conventional tests in patients with Type 1 diabetes. Diabetes Care 23(11), 1686–1693 (2000).
   PubMedGoogle Scholar
• Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 33(2), 434–441 (2010).
   PubMed Web of Science ®Google Scholar
• Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes. Metab. Rev. 10(4), 339–383 (1994).
   PubMed Web of Science ®Google Scholar
• Ewing DJ, Clarke BF. Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care 9(6), 648–665 (1986).
   PubMed Web of Science ®Google Scholar
• Maser RE, Lenhard MJ. Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. J. Clin. Endocrinol. Metab. 90(10), 5896–5903 (2005).
   PubMedGoogle Scholar
• Kahn JK, Zola B, Juni JE, Vinik AI. Decreased exercise heart rate and blood pressure response in diabetic subjects with cardiac autonomic neuropathy. Diabetes Care 9(4), 389–394 (1986).
   PubMed Web of Science ®Google Scholar
• Roy TM, Peterson HR, Snider HL et al. Autonomic influence on cardiovascular performance in diabetic subjects. Am. J. Med. 87(4), 382–388 (1989).
   PubMed Web of Science ®Google Scholar
• Kahn JK, Zola B, Juni JE, Vinik AI. Radionuclide assessment of left ventricular diastolic filling in diabetes mellitus with and without cardiac autonomic neuropathy. J. Am. Coll. Cardiol. 7(6), 1303–1309 (1986).
   PubMedGoogle Scholar
• Burgos LG, Ebert TJ, Asiddao C et al. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology 70(4), 591–597 (1989).
   PubMed Web of Science ®Google Scholar
• Knüttgen D, Büttner-Belz U, Gernot A, Doehn M. [Unstable blood pressure during anesthesia in diabetic patients with autonomic neuropathy]. Anasth. Intensivther. Notfallmed. 25(4), 256–262 (1990).
   PubMedGoogle Scholar
• Latson TW, Ashmore TH, Reinhart DJ, Klein KW, Giesecke AH. Autonomic reflex dysfunction in patients presenting for elective surgery is associated with hypotension after anesthesia induction. Anesthesiology 80(2), 326–337 (1994).
   PubMed Web of Science ®Google Scholar
• Kitamura A, Hoshino T, Kon T, Ogawa R. Patients with diabetic neuropathy are at risk of a greater intraoperative reduction in core temperature. Anesthesiology 92(5), 1311–1318 (2000).
   PubMed Web of Science ®Google Scholar
• Sobotka PA, Liss HP, Vinik AI. Impaired hypoxic ventilatory drive in diabetic patients with autonomic neuropathy. J. Clin. Endocrinol. Metab. 62(4), 658–663 (1986).
   PubMedGoogle Scholar
• Low PA, Walsh JC, Huang CY, McLeod JG. The sympathetic nervous system in diabetic neuropathy. A clinical and pathological study. Brain 98(3), 341–356 (1975).
   PubMed Web of Science ®Google Scholar
• Page MM, Watkins PJ. Provocation of postural hypotension by insulin in diabetic autonomic neuropathy. Diabetes 25(2), 90–95 (1976).
   PubMed Web of Science ®Google Scholar
• Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 8(5), 491–498 (1985).
   PubMed Web of Science ®Google Scholar
• Kempler P, Tesfaye S, Chaturvedi N et al. Blood pressure response to standing in the diagnosis of autonomic neuropathy: the EURODIAB IDDM Complications Study. Arch. Physiol. Biochem. 109(3), 215–222 (2001).
   PubMedGoogle Scholar
• Low PA. Prevalence of orthostatic hypotension. Clin. Auton. Res. 18(Suppl. 1), 8–13 (2008).
   PubMed Web of Science ®Google Scholar
• Stewart JM, Medow MS, Montgomery LD. Local vascular responses affecting blood flow in postural tachycardia syndrome. Am. J. Physiol. Heart Circ. Physiol. 285(6), H2749–H2756 (2003).
   Google Scholar
• Grubb BP, Kosinski DJ, Boehm K, Kip K. The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing. Pacing Clin. Electrophysiol. 20(9 Pt 1), 2205–2212 (1997).
   PubMedGoogle Scholar
• Stewart JM, Montgomery LD. Regional blood volume and peripheral blood flow in postural tachycardia syndrome. Am. J. Physiol. Heart Circ. Physiol. 287(3), H1319–H1327 (2004).
   Google Scholar
• Rosen SD, Camici PG. The brain–heart axis in the perception of cardiac pain: the elusive link between ischaemia and pain. Ann. Med. 32(5), 350–364 (2000).
   PubMed Web of Science ®Google Scholar
• Wackers FJ, Young LH, Inzucchi SE et al.; Detection of Ischemia in Asymptomatic Diabetics Investigators. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 27(8), 1954–1961 (2004).
   PubMed Web of Science ®Google Scholar
• Margolis JR, Kannel WS, Feinleib M, Dawber TR, McNamara PM. Clinical features of unrecognized myocardial infarction–silent and symptomatic. Eighteen year follow-up: the Framingham study. Am. J. Cardiol. 32(1), 1–7 (1973).
   PubMed Web of Science ®Google Scholar
• Canto JG, Shlipak MG, Rogers WJ et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 283(24), 3223–3229 (2000).
   PubMed Web of Science ®Google Scholar
• Ambepityia G, Kopelman PG, Ingram D, Swash M, Mills PG, Timmis AD. Exertional myocardial ischemia in diabetes: a quantitative analysis of anginal perceptual threshold and the influence of autonomic function. J. Am. Coll. Cardiol. 15(1), 72–77 (1990).
   PubMedGoogle Scholar
• Schönauer M, Thomas A, Morbach S, Niebauer J, Schönauer U, Thiele H. Cardiac autonomic diabetic neuropathy. Diab. Vasc. Dis. Res. 5(4), 336–344 (2008).
   PubMed Web of Science ®Google Scholar
• Mustonen J, Uusitupa M, Länsimies E, Vainio P, Laakso M, Pyörälä K. Autonomic nervous function and its relationship to cardiac performance in middle-aged diabetic patients without clinically evident cardiovascular disease. J. Intern. Med. 232(1), 65–72 (1992).
   PubMedGoogle Scholar
• Didangelos TP, Arsos GA, Karamitsos DT, Athyros VG, Karatzas ND. Left ventricular systolic and diastolic function in normotensive Type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study. Diabetes Care 26(7), 1955–1960 (2003).
   PubMedGoogle Scholar
• Yokoyama I, Ohtake T, Momomura S et al. Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. Diabetes 47(1), 119–124 (1998).
   PubMedGoogle Scholar
• Karayannis G, Giamouzis G, Alexandridis E et al. Prevalence of impaired coronary flow reserve and its association with left ventricular diastolic function in asymptomatic individuals with major cardiovascular risk factors. Eur. J. Cardiovasc. Prev. Rehabil. 18(2), 326–333 (2011).
   PubMedGoogle Scholar
• Perin PC, Maule S, Quadri R. Sympathetic nervous system, diabetes, and hypertension. Clin. Exp. Hypertens. 23(1–2), 45–55 (2001).
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J. Am. Coll. Cardiol. 54(19), 1747–1762 (2009).
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Giamouzis G, Butler J. The importance of managing diabetes correctly to prevent heart failure. Expert Rev. Cardiovasc. Ther. 9(3), 257–259 (2011).
   PubMedGoogle Scholar
• Ejaz A, LoGerfo FW, Pradhan L. Diabetic neuropathy and heart failure: role of neuropeptides. Expert Rev. Mol. Med. 13, e26 (2011).
   Google Scholar
• Giamouzis G, Kalogeropoulos A, Georgiopoulou V et al. Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. J. Card. Fail. 17(1), 54–75 (2011).
   PubMed Web of Science ®Google Scholar
• Giamouzis G, Butler J. Relationship between heart failure and lipids: the paradigm continues to evolve. J. Card. Fail. 13(4), 254–258 (2007).
   PubMedGoogle Scholar
• Pop-Busui R, Kirkwood I, Schmid H et al. Sympathetic dysfunction in Type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J. Am. Coll. Cardiol. 44(12), 2368–2374 (2004).
   PubMedGoogle Scholar
• Taskiran M, Rasmussen V, Rasmussen B et al. Left ventricular dysfunction in normotensive Type 1 diabetic patients: the impact of autonomic neuropathy. Diabet. Med. 21(6), 524–530 (2004).
   PubMedGoogle Scholar
• Johnson BF, Nesto RW, Pfeifer MA et al. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care 27(2), 448–454 (2004).
   PubMed Web of Science ®Google Scholar
• Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 101(5), 558–569 (2000).
   PubMed Web of Science ®Google Scholar
• Karamitsos TD, Karvounis HI, Didangelos T, Parcharidis GE, Karamitsos DT. Impact of autonomic neuropathy on left ventricular function in normotensive Type 1 diabetic patients: a tissue Doppler echocardiographic study. Diabetes Care 31(2), 325–327 (2008).
   PubMedGoogle Scholar
• Sugiyama T, Kurata C, Tawarahara K, Nakano T. Is abnormal iodine-123-MIBG kinetics associated with left ventricular dysfunction in patients with diabetes mellitus? J. Nucl. Cardiol. 7(6), 562–568 (2000).
   PubMedGoogle Scholar
• Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH; EURODIAB Prospective Complications Study Group. Relationship between risk factors and mortality in Type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 31(7), 1360–1366 (2008).
   PubMed Web of Science ®Google Scholar
• Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 26(6), 1895–1901 (2003).
   PubMed Web of Science ®Google Scholar
• Tsuji H, Venditti FJ Jr, Manders ES et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 90(2), 878–883 (1994).
   PubMed Web of Science ®Google Scholar
• Pagani M. Heart rate variability and autonomic diabetic neuropathy. Diabetes Nutr. Metab. 13(6), 341–346 (2000).
   PubMedGoogle Scholar
• Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am. J. Cardiol. 59(4), 256–262 (1987).
   PubMed Web of Science ®Google Scholar
• La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 351(9101), 478–484 (1998).
   PubMed Web of Science ®Google Scholar
• Ewing DJ, Campbell IW, Clarke BF. Heart rate changes in diabetes mellitus. Lancet 1(8213), 183–186 (1981).
   PubMed Web of Science ®Google Scholar
• Palatini P, Benetos A, Grassi G et al.; European Society of Hypertension. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J. Hypertens. 24(4), 603–610 (2006).
   PubMed Web of Science ®Google Scholar
• Ziegler D, Zentai CP, Perz S et al.; KORA Study Group. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 31(3), 556–561 (2008).
   PubMed Web of Science ®Google Scholar
• Veglio M, Chinaglia A, Cavallo-Perin P. QT interval, cardiovascular risk factors and risk of death in diabetes. J. Endocrinol. Invest. 27(2), 175–181 (2004).
   PubMed Web of Science ®Google Scholar
• Page MM, Watkins PJ. Cardiorespiratory arrest and diabetic autonomic neuropathy. Lancet 1(8054), 14–16 (1978).
   PubMed Web of Science ®Google Scholar
• Spallone V, Maiello MR, Cicconetti E, Menzinger G. Autonomic neuropathy and cardiovascular risk factors in insulin-dependent and non insulin-dependent diabetes. Diabetes Res. Clin. Pract. 34(3), 169–179 (1997).
   PubMedGoogle Scholar
• Cohen JA, Jeffers BW, Faldut D, Marcoux M, Schrier RW. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM). Muscle Nerve 21(1), 72–80 (1998).
   PubMedGoogle Scholar
• Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 11(10), 821–827 (1988).
   PubMed Web of Science ®Google Scholar
• Navarro X, Kennedy WR, Sutherland DE. Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation. Diabetologia 34(Suppl. 1), S108–S112 (1991).
   Google Scholar
• O’Brien IA, McFadden JP, Corrall RJ. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q. J. Med. 79(290), 495–502 (1991).
   PubMedGoogle Scholar
• Rathmann W, Ziegler D, Jahnke M, Haastert B, Gries FA. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet. Med. 10(9), 820–824 (1993).
   PubMedGoogle Scholar
• Kahn JK, Sisson JC, Vinik AI. Prediction of sudden cardiac death in diabetic autonomic neuropathy. J. Nucl. Med. 29(9), 1605–1606 (1988).
   PubMed Web of Science ®Google Scholar
• Miettinen H, Lehto S, Salomaa V et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 21(1), 69–75 (1998).
   PubMed Web of Science ®Google Scholar
• Fava S, Azzopardi J, Muscat HA, Fenech FF. Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care 16(12), 1615–1618 (1993).
   PubMed Web of Science ®Google Scholar
• Katz A, Liberty IF, Porath A, Ovsyshcher I, Prystowsky EN. A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction. Am. Heart J. 138(1 Pt 1), 32–38 (1999).
   PubMedGoogle Scholar
• Ewing DJ, Campbell IW, Burt AA, Clarke BF. Vascular reflexes in diabetic autonomic neuropathy. Lancet 2(7842), 1354–1356 (1973).
   PubMed Web of Science ®Google Scholar
• Pfeifer MA, Cook D, Brodsky J et al. Quantitative evaluation of cardiac parasympathetic activity in normal and diabetic man. Diabetes 31(4 Pt 1), 339–345 (1982).
   PubMedGoogle Scholar
• Boulton AJ, Vinik AI, Arezzo JC et al.; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28(4), 956–962 (2005).
   PubMed Web of Science ®Google Scholar
• Spallone V, Bellavere F, Scionti L et al.; Diabetic Neuropathy Study Group of the Italian Society of Diabetology. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr. Metab. Cardiovasc. Dis. 21(1), 69–78 (2011).
   PubMed Web of Science ®Google Scholar
• Ziegler D, Laux G, Dannehl K et al. Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet. Med. 9(2), 166–175 (1992).
   PubMed Web of Science ®Google Scholar
• Levitt NS, Stansberry KB, Wynchank S, Vinik AI. The natural progression of autonomic neuropathy and autonomic function tests in a cohort of people with IDDM. Diabetes Care 19(7), 751–754 (1996).
   PubMedGoogle Scholar
• Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen LB. Diabetic neuropathies. Diabetes Care 15(12), 1926–1975 (1992).
   PubMed Web of Science ®Google Scholar
• Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 46, 1470 (1996).
   PubMed Web of Science ®Google Scholar
• Spallone V, Morganti R, Fedele T, D’Amato C, Maiello MR. Reappraisal of the diagnostic role of orthostatic hypotension in diabetes. Clin. Auton. Res. 19(1), 58–64 (2009).
   PubMedGoogle Scholar
• Schwartz PJ, Stramba-Badiale M, Segantini A et al. Prolongation of the QT interval and the sudden infant death syndrome. N. Engl. J. Med. 338(24), 1709–1714 (1998).
   PubMed Web of Science ®Google Scholar
• de Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, Grobbee DE. Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. Eur. Heart J. 20(4), 278–284 (1999).
   PubMed Web of Science ®Google Scholar
• Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 83(6), 1888–1894 (1991).
   PubMed Web of Science ®Google Scholar
• Suys BE, Huybrechts SJ, De Wolf D et al. QTc interval prolongation and QTc dispersion in children and adolescents with Type 1 diabetes. J. Pediatr. 141(1), 59–63 (2002).
   PubMed Web of Science ®Google Scholar
• Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 33(6), 1389–1394 (2010).
   PubMed Web of Science ®Google Scholar
• Whitsel EA, Boyko EJ, Siscovick DS. Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes: a meta-analysis. Diabetes Care 23(2), 241–247 (2000).
   PubMed Web of Science ®Google Scholar
• Psallas M, Tentolouris N, Cokkinos A, Papadogiannis D, Cokkinos DV, Katsilambros N. QT dispersion: comparison between diabetic and non-diabetic individuals and correlation with cardiac autonomic neuropathy. Hellenic J. Cardiol. 47(5), 255–262 (2006).
   PubMedGoogle Scholar
• Voulgari Ch, Tentolouris N, Moyssakis I et al. Spatial QRS-T angle: association with diabetes and left ventricular performance. Eur. J. Clin. Invest. 36(9), 608–613 (2006).
   PubMedGoogle Scholar
• Montano N, Ruscone TG, Porta A, Lombardi F, Pagani M, Malliani A. Power spectrum analysis of heart rate variability to assess the changes in sympathovagal balance during graded orthostatic tilt. Circulation 90(4), 1826–1831 (1994).
   PubMed Web of Science ®Google Scholar
• Pagani M, Malliani A. Interpreting oscillations of muscle sympathetic nerve activity and heart rate variability. J. Hypertens. 18(12), 1709–1719 (2000).
   PubMed Web of Science ®Google Scholar
• Bernardi L, Spallone V, Stevens M et al.; on behalf of the Toronto Consensus Panel on Diabetic Neuropathy*. Investigation methods for cardiac autonomic function in human research studies. Diabetes Metab. Res. Rev. 27(7), 654–664 (2011).
   PubMed Web of Science ®Google Scholar
• Low PA, Denq JC, Opfer-Gehrking TL, Dyck PJ, O’Brien PC, Slezak JM. Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects. Muscle Nerve 20(12), 1561–1568 (1997).
   PubMed Web of Science ®Google Scholar
• Gelber DA, Pfeifer M, Dawson B, Schumer M. Cardiovascular autonomic nervous system tests: determination of normative values and effect of confounding variables. J. Auton. Nerv. Syst. 62(1–2), 40–44 (1997).
   PubMedGoogle Scholar
• Howorka K, Pumprla J, Schabmann A. Optimal parameters of short-term heart rate spectrogram for routine evaluation of diabetic cardiovascular autonomic neuropathy. J. Auton. Nerv. Syst. 69(2–3), 164–172 (1998).
   PubMedGoogle Scholar
• Bigger JT Jr, Fleiss JL, Rolnitzky LM, Steinman RC. Stability over time of heart period variability in patients with previous myocardial infarction and ventricular arrhythmias. The CAPS and ESVEM investigators. Am. J. Cardiol. 69(8), 718–723 (1992).
   PubMed Web of Science ®Google Scholar
• Spallone V, Bernardi L, Ricordi L et al. Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. Diabetes 42(12), 1745–1752 (1993).
   PubMed Web of Science ®Google Scholar
• Mansia G, De Backer G, Dominiczak A et al.; European Society of HypertensionEuropean Society of Cardiology. 2007 ESH-ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 16(3), 135–232 (2007).
   PubMed Web of Science ®Google Scholar
• Spallone V, Maiello MR, Morganti R, Mandica S, Frajese G. Usefulness of ambulatory blood pressure monitoring in predicting the presence of autonomic neuropathy in Type I diabetic patients. J. Hum. Hypertens. 21(5), 381–386 (2007).
   PubMedGoogle Scholar
• Raffel DM, Wieland DM. Assessment of cardiac sympathetic nerve integrity with positron emission tomography. Nucl. Med. Biol. 28(5), 541–559 (2001).
   PubMedGoogle Scholar
• Stevens MJ, Raffel DM, Allman KC, Schwaiger M, Wieland DM. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Metab. Clin. Exp. 48(1), 92–101 (1999).
   PubMed Web of Science ®Google Scholar
• Schnell O, Muhr D, Weiss M, Dresel S, Haslbeck M, Standl E. Reduced myocardial 123I-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients. Diabetes 45(6), 801–805 (1996).
   PubMed Web of Science ®Google Scholar
• Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93, 1043–1065 (1996).
   PubMed Web of Science ®Google Scholar
• La Rovere MT, Pinna GD, Maestri R et al. Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. J. Am. Coll. Cardiol. 53(2), 193–199 (2009).
   PubMedGoogle Scholar
• Johansson M, Gao SA, Friberg P et al. Baroreflex effectiveness index and baroreflex sensitivity predict all-cause mortality and sudden death in hypertensive patients with chronic renal failure. J. Hypertens. 25(1), 163–168 (2007).
   PubMedGoogle Scholar
• Gerritsen J, Dekker JM, TenVoorde BJ et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care 24(10), 1793–1798 (2001).
   PubMed Web of Science ®Google Scholar
• Rosengård-Bärlund M, Bernardi L, Fagerudd J et al.; FinnDiane Study Group. Early autonomic dysfunction in Type 1 diabetes: a reversible disorder? Diabetologia 52(6), 1164–1172 (2009).
   PubMed Web of Science ®Google Scholar
• Frattola A, Parati G, Gamba P et al. Time and frequency domain estimates of spontaneous baroreflex sensitivity provide early detection of autonomic dysfunction in diabetes mellitus. Diabetologia 40(12), 1470–1475 (1997).
   PubMed Web of Science ®Google Scholar
• Weston PJ, James MA, Panerai RB, McNally PG, Potter JF, Thurston H. Evidence of defective cardiovascular regulation in insulin-dependent diabetic patients without clinical autonomic dysfunction. Diabetes Res. Clin. Pract. 42(3), 141–148 (1998).
   PubMed Web of Science ®Google Scholar
• Ziegler D, Laude D, Akila F, Elghozi JL. Time- and frequency-domain estimation of early diabetic cardiovascular autonomic neuropathy. Clin. Auton. Res. 11(6), 369–376 (2001).
   PubMed Web of Science ®Google Scholar
• Hamner JW, Taylor JA. Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. J. Appl. Physiol. 91(3), 1199–1206 (2001).
   PubMedGoogle Scholar
• Bernardi L. Clinical evaluation of arterial baroreflex activity in diabetes. Diabetes Nutr. Metab. 13(6), 331–340 (2000).
   PubMedGoogle Scholar
• Huggett RJ, Scott EM, Gilbey SG, Bannister J, Mackintosh AF, Mary DA. Disparity of autonomic control in Type 2 diabetes mellitus. Diabetologia 48(1), 172–179 (2005).
   PubMedGoogle Scholar
• Hoffman RP, Sinkey CA, Anderson EA. Microneurographically determined muscle sympathetic nerve activity levels are reproducible in insulin-dependent diabetes mellitus. J. Diabetes Complicat. 12(6), 307–310 (1998).
   PubMedGoogle Scholar
• Cryer PE. Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system. N. Engl. J. Med. 303(8), 436–444 (1980).
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Holmes C, Sharabi Y, Brentzel S, Eisenhofer G. Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension. Neurology 60(8), 1327–1332 (2003).
   PubMed Web of Science ®Google Scholar
• Hilsted J. Catecholamines and diabetic autonomic neuropathy. Diabet. Med. 12(4), 296–297 (1995).
   PubMedGoogle Scholar
• Kahn R. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Autonomic nervous system testing. Diabetes Care 15(8), 1095–1103 (1992).
   PubMedGoogle Scholar
• Laederach-Hofmann K, Mussgay L, Winter A, Klinkenberg N, Rüddel H. Early autonomic dysfunction in patients with diabetes mellitus assessed by spectral analysis of heart rate and blood pressure variability. Clin. Physiol. 19(2), 97–106 (1999).
   PubMedGoogle Scholar
• Agelink MW, Malessa R, Baumann B et al. Standardized tests of heart rate variability: normal ranges obtained from 309 healthy humans, and effects of age, gender, and heart rate. Clin. Auton. Res. 11(2), 99–108 (2001).
   PubMed Web of Science ®Google Scholar
• May O, Arildsen H. Long-term predictive power of simple function tests for cardiovascular autonomic neuropathy in diabetes: a population-based study. Acta Diabetol. 48(4), 311–316 (2011).
   PubMedGoogle Scholar
• Axelrod S, Lishner M, Oz O, Bernheim J, Ravid M. Spectral analysis of fluctuations in heart rate: an objective evaluation of autonomic nervous control in chronic renal failure. Nephron 45(3), 202–206 (1987).
   PubMed Web of Science ®Google Scholar
• Consensus statement: report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care 11, 592–597 (1988).
   PubMed Web of Science ®Google Scholar
• Bellavere F, Thomaseth K, Cobelli C et al. Evaluation of the vagal–sympathetic interaction in diabetics with autonomic neuropathy through power spectrum density analysis of the heart rate. A critical revision of the natural history of diabetic autonomic neuropathy is possible. Funct. Neurol. 4(2), 177–181 (1989).
   PubMedGoogle Scholar
• Howorka K, Pumprla J, Haber P, Koller-Strametz J, Mondrzyk J, Schabmann A. Effects of physical training on heart rate variability in diabetic patients with various degrees of cardiovascular autonomic neuropathy. Cardiovasc. Res. 34(1), 206–214 (1997).
   PubMed Web of Science ®Google Scholar
• Ikeda T, Iwata K, Tanaka Y. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus. Diabetes Res. Clin. Pract. 43(3), 193–198 (1999).
   PubMed Web of Science ®Google Scholar
• Malfatto G, Facchini M, Bragato R, Branzi G, Sala L, Leonetti G. Short and long term effects of exercise training on the tonic autonomic modulation of heart rate variability after myocardial infarction. Eur. Heart J. 17(4), 532–538 (1996).
   PubMed Web of Science ®Google Scholar
• Loimaala A, Huikuri H, Oja P, Pasanen M, Vuori I. Controlled 5-mo aerobic training improves heart rate but not heart rate variability or baroreflex sensitivity. J. Appl. Physiol. 89(5), 1825–1829 (2000).
   PubMed Web of Science ®Google Scholar
• Loimaala A, Huikuri HV, Kööbi T, Rinne M, Nenonen A, Vuori I. Exercise training improves baroreflex sensitivity in Type 2 diabetes. Diabetes 52(7), 1837–1842 (2003).
   PubMedGoogle Scholar
• Osztovits J, Horváth T, Littvay L et al. Effects of genetic vs. environmental factors on cardiovascular autonomic function: a twin study. Diabet. Med. 28(10), 1241–1248 (2011).
   PubMedGoogle Scholar
• Habib AA, Brannagan TH 3rd. Therapeutic strategies for diabetic neuropathy. Curr. Neurol. Neurosci. Rep. 10(2), 92–100 (2010).
   PubMedGoogle Scholar
• Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 53(3), 580–591 (1999).
   PubMed Web of Science ®Google Scholar
• Gabbay KH. Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004? Curr. Diab. Rep. 4(6), 405–408 (2004).
   PubMedGoogle Scholar
• Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 29(1), 68–72 (2006).
   PubMed Web of Science ®Google Scholar
• Hotta N, Toyota T, Matsuoka K et al.; SNK-860 Diabetic Neuropathy Study Group. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 24(10), 1776–1782 (2001).
   PubMed Web of Science ®Google Scholar
• Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kikkawa R. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed. Pharmacother. 49(6), 269–277 (1995).
   PubMed Web of Science ®Google Scholar
• Várkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes. Obes. Metab. 10(2), 99–108 (2008).
   PubMed Web of Science ®Google Scholar
• Tankova T, Koev D, Dakovska L. Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study). Rom. J. Intern. Med. 42(2), 457–464 (2004).
   PubMedGoogle Scholar
• Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 20(3), 369–373 (1997).
   PubMed Web of Science ®Google Scholar
• Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp. Clin. Endocrinol. Diabetes 107(7), 421–430 (1999).
   PubMed Web of Science ®Google Scholar
• Manzella D, Barbieri M, Ragno E, Paolisso G. Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with Type 2 diabetes. Am. J. Clin. Nutr. 73(6), 1052–1057 (2001).
   PubMed Web of Science ®Google Scholar
• Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 142(1), 37–46 (2005).
   PubMed Web of Science ®Google Scholar
• Ermis N, Gullu H, Caliskan M, Unsal A, Kulaksizoglu M, Muderrisoglu H. Gabapentin therapy improves heart rate variability in diabetic patients with peripheral neuropathy. J. Diabetes Complicat. 24(4), 229–233 (2010).
   PubMedGoogle Scholar
• Cameron NE, Cotter MA. Diabetes causes an early reduction in autonomic ganglion blood flow in rats. J. Diabetes Complicat. 15(4), 198–202 (2001).
   PubMedGoogle Scholar
• Tesfaye S, Harris N, Jakubowski JJ et al. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia 36(12), 1266–1274 (1993).
   PubMed Web of Science ®Google Scholar
• Kontopoulos AG, Athyros VG, Didangelos TP et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 20(3), 355–361 (1997).
   PubMed Web of Science ®Google Scholar
• Malik RA, Williamson S, Abbott C et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 352(9145), 1978–1981 (1998).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341(10), 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Yee KM, Struthers AD. Aldosterone blunts the baroreflex response in man. Clin. Sci. 95(6), 687–692 (1998).
   PubMed Web of Science ®Google Scholar
• Fletcher J, Buch AN, Routledge HC, Chowdhary S, Coote JH, Townend JN. Acute aldosterone antagonism improves cardiac vagal control in humans. J. Am. Coll. Cardiol. 43(7), 1270–1275 (2004).
   PubMedGoogle Scholar
• MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc. Res. 35(1), 30–34 (1997).
   PubMed Web of Science ®Google Scholar
• Korkmaz ME, Müderrisoglu H, Uluçam M, Ozin B. Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. Am. J. Cardiol. 86(6), 649–653 (2000).
   PubMed Web of Science ®Google Scholar
• Davies JI, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes. Diabetologia 47(10), 1687–1694 (2004).
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Giamouzis G, Kelepeshis G, Sitafidis G, Skoularigis J, Demopoulos V. Acute hemodynamic effects of moderate doses of nebivolol versus metoprolol in patients with systolic heart failure. Int. J. Clin. Pharmacol. Ther. 45(2), 71–77 (2007).
   PubMed Web of Science ®Google Scholar
• Ebbehøj E, Poulsen PL, Hansen KW, Knudsen ST, Mølgaard H, Mogensen CE. Effects on heart rate variability of metoprolol supplementary to ongoing ACE-inhibitor treatment in Type I diabetic patients with abnormal albuminuria. Diabetologia 45(7), 965–975 (2002).
   PubMedGoogle Scholar
• Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28(2), 103–117 (1995).
   PubMed Web of Science ®Google Scholar
• Giamouzis G, Triposkiadis F, Butler J. Metformin use in patients with diabetes mellitus and heart failure: friend or foe? J. Card. Fail. 16(3), 207–210 (2010).
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T et al.; VADT Investigators. Glucose control and vascular complications in veterans with Type 2 diabetes. N. Engl. J. Med. 360(2), 129–139 (2009).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358(24), 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 358(24), 2560–2572 (2008).
   PubMed Web of Science ®Google Scholar
• Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10–11 February 1998, Miami, Florida. American Diabetes Association. Diabetes Care 21, 1551–1559 (1998).
   PubMedGoogle Scholar
• Lièvre MM, Moulin P, Thivolet C et al.; DYNAMIT investigators. Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. Trials 12, 23 (2011).
   PubMedGoogle Scholar
• Frye RL, August P, Brooks MM et al.; BARI 2D Study Group. A randomized trial of therapies for Type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360(24), 2503–2515 (2009).
   PubMed Web of Science ®Google Scholar
• Giamouzis G, Agha SA, Ekundayo OJ et al. Incident coronary revascularization and subsequent mortality in chronic heart failure: a propensity-matched study. Int. J. Cardiol. 140(1), 55–59 (2010).
   PubMedGoogle Scholar
• Graham I, Atar D, Borch-Johnsen K et al.; European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 28(19), 2375–2414 (2007).
   PubMed Web of Science ®Google Scholar
• Jordan J, Shannon JR, Black BK et al. The pressor response to water drinking in humans: a sympathetic reflex? Circulation 101(5), 504–509 (2000).
   PubMed Web of Science ®Google Scholar
• Vinik AI. Diabetic neuropathy: pathogenesis and therapy. Am. J. Med. 107(2B), 17S–26S (1999).
   PubMedGoogle Scholar
• Freeman R. Treatment of orthostatic hypotension. Semin. Neurol. 23(4), 435–442 (2003).
   PubMed Web of Science ®Google Scholar
• Hoeldtke RD, Horvath GG, Bryner KD, Hobbs GR. Treatment of orthostatic hypotension with midodrine and octreotide. J. Clin. Endocrinol. Metab. 83(2), 339–343 (1998).
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Chey W, Stevens MJ. Severe hypertension induced by the long-acting somatostatin analogue sandostatin LAR in a patient with diabetic autonomic neuropathy. J. Clin. Endocrinol. Metab. 85(3), 943–946 (2000).
   PubMedGoogle Scholar
• Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J. Neurol. Neurosurg. Psychiatr. 74(9), 1294–1298 (2003).
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Pelat M, Verwaerde P et al. Fluoxetine in orthostatic hypotension of Parkinson’s disease: a clinical and experimental pilot study. Fundam. Clin. Pharmacol. 12(4), 398–402 (1998).
   PubMedGoogle Scholar
• Brahmbhatt R, Baggaley P, Hockings B. Normalization of blood pressure in a patient with severe orthostatic hypotension and supine hypertension using clonidine. Hypertension 37(6), E24 (2001).
   Google Scholar
• Roche E, Enseñat-Waser R, Reig JA, Jones J, León-Quinto T, Soria B. Therapeutic potential of stem cells in diabetes. Handb. Exp. Pharmacol. (174), 147–167 (2006).
   PubMedGoogle Scholar
• Chattopadhyay M, Krisky D, Wolfe D, Glorioso JC, Mata M, Fink DJ. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther. 12(18), 1377–1384 (2005).
   PubMed Web of Science ®Google Scholar
• Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat. Rev. Neurol. 7(10), 573–583 (2011).
   PubMed Web of Science ®Google Scholar
• Stevens MJ, Dayanikli F, Raffel DM et al. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy. J. Am. Coll. Cardiol. 31, 1575–1584 (1998).
   PubMed Web of Science ®Google Scholar
• Ziegler D, Weise F, Langen KJ et al. Effect of glycaemic control on myocardial sympathetic innervation assessed by [123I]metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 41(4), 443–451 (1998).
   PubMed Web of Science ®Google Scholar